YES1 and cancer: YES1 amplification and overexpression have also been found to be mechanisms for acquired resistance to different cancer treatments, as indicated by the inhibition of YES1 expression increasing cell sensitivity to chemotherapeutic drugs or targeted drugs, with dasatinib (an SFK inhibitor) treatment overcoming this drug resistance (Garmendia et al., 2019; Hamanaka et al., 2019; Garmendia et al., 2022).